Telix Pharmaceuticals (TLX) Stock: Buy, Sell, or Hold?
TLX - Telix Pharmaceuticals Limited American Depositary Shares
$10.72
-0.25 (-2.28%)
▼
5d:
-5.22%
30d:
-1.2%
90d:
-9.69%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Jul 02, 2026
0d
Get Alerted When TLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: TLX shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: TLX shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: TLX is currently trading at $10.72, which is considered oversold relative to its 30-day fair value range of $11.17 to $12.14. From a valuation perspective, the stock is trading at a discount (Forward PE: -282.1) compared to its historical average (35.2). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TLX is in a strong downtrend. The price is currently testing key support at $10.72. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TLX scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19.58 (+82.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TLX is in a strong downtrend. The price is currently testing key support at $10.72. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TLX scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $19.58 (+82.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$11.17 -
$12.14
Company Quality Score
36/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 82.6% below Wall St target ($19.58)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 36/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$11.17 -
$12.14
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$10.72
Resistance Level
$12.80
Current Trend
Strong Downtrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-282.11
Wall Street Target
$19.58
(+82.6%)
Revenue Growth (YoY)
22.3%
Profit Margin
3.8%
PE vs Historical
-282.1 vs 35.2
CHEAP
Share & Embed Analysis
Last updated: October 02, 2026 8:31 AM ET
Data refreshes hourly during market hours. Next update: 9:31 AM
Data refreshes hourly during market hours. Next update: 9:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TLX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 51 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$851 | 53 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 51 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 58 HOLD |
